KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Other Non-Current Assets (2016 - 2025)

Nektar Therapeutics has reported Other Non-Current Assets over the past 16 years, most recently at $5.6 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $5.6 million for Q4 2025, up 21.54% from a year ago — trailing twelve months through Dec 2025 was $5.6 million (up 21.54% YoY), and the annual figure for FY2025 was $5.6 million, up 21.54%.
  • Other Non-Current Assets for Q4 2025 was $5.6 million at Nektar Therapeutics, up from $5.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for NKTR hit a ceiling of $5.6 million in Q4 2025 and a floor of $344000.0 in Q2 2021.
  • Median Other Non-Current Assets over the past 5 years was $3.5 million (2021), compared with a mean of $3.3 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 75.65% in 2021 and later soared 549.42% in 2022.
  • Nektar Therapeutics' Other Non-Current Assets stood at $2.7 million in 2021, then decreased by 18.19% to $2.2 million in 2022, then soared by 106.86% to $4.6 million in 2023, then increased by 0.06% to $4.6 million in 2024, then rose by 21.54% to $5.6 million in 2025.
  • The last three reported values for Other Non-Current Assets were $5.6 million (Q4 2025), $5.2 million (Q3 2025), and $5.0 million (Q2 2025) per Business Quant data.